

## Platelets large cells ratio (P-LCR)-A new platelets indices use as a risk assessment prognostic tool for post myocardial infarction patients

**Dr.Dinesh Jain, , Dr. Shivam Yadav**  
<sup>1</sup>Proffessor-Medicine <sup>2</sup>Resident Medicine  
DMCH Ludhiana

**Corresponding Author:**

**Dr.Dinesh Jain**  
Medicine DMCH Ludhiana

**Received: 20 November 2018**

**Published: 02 December 2018**

Type of Publication: Original Research Paper

Conflicts of Interest: Nil

### ABSTRACT

**OBJECTIVES & AIMS:** To evaluate and identify new prognostic markers suggested in recent studies for coronary heart disease, raised platelets large cells ratio (P-LCR)) has been found to be associated with poor prognosis after recent myocardial infarction. To evaluate the relationship between raised P-LCR and mortality/ morbidity after the initial attack of myocardial infarction (MI). Increased platelets-LCR has been associated with adverse outcomes. We studied the association between raised P-LCR during hospital course with clinical outcomes survival index of patients with acute myocardial infarction (AMI).

**MATERIAL & METHODS:** Blood was collected in a sterile EDTA containing tube and processed following our established ISO certified hospital based laboratory protocol .A complete blood counting including HB%,PCV, Red cell indices ,platelet count, total white cell count and PDW was done by Automated blood cell counter. Level of Troponin I done by automated mini vidas bioanalyser.

**CONCLUSION:** We found significant correlation in patients with post MI along with high P-LCR. P-LCR is an inexpensive cost effective and easily available laboratory test,high P-LCR with high troponin I for post MI have poor outcome of patients' it could be used for mortality and morbidity risk assessment and follow up the patients after MI .We found that high P-LCR of raised troponin I pt. shows poor prognosis.Confirmation of MI done by troponin I level of every patients.

**Keywords:** myocardial infarction, platelets large cells ratio.

### INTRODUCTION

#### Material & Methods

**Study area and design-** This present study was conducted at the Dayanand Medical College and associated hospital, ludhiana. The study was designed as an observational retrograde with prospective hospital based study over a period of time from January to December 2014.

**Ethical consideration-** Blood was collected in a sterile EDTA tube and plaint tube and processed following our established laboratory protocol then generate the report of each patient. Take informed consent was obtained from all study participant for use of your blood sample for medical research after

doing physician request investigating and generate the report.

**Patient's selection criteria-**The study target all patients on the basis of clinical signs, symptoms and ECG ST elevation with high troponin I level, history by patients, attendants and data records. We included both emergency and IPD patients with all age groups, male and female both gender for study. Sample size is 100 patients.

**Laboratory investigations** Blood was collected in a sterile EDTA containing tube and processed following our established laboratory protocol .A complete blood counting including HB%, PCV, Red cell indices, platelet count and total white cell count

and differential was done by automated blood cell counter and peripheral blood smear examination. The cell count indices including RBC, WBC count with differential along with morphological changes further confirmed by manual oil immersion smear study method.

#### Materials:

Purple vacutainer tube or capillary collector (EDTA) ethylenediaminetetraacetate, Slides and blue capillary tube, Needle or lancet, Vacutainer holder, Alcohol swab, Cotton balls, Absorbent materials, Slide case and hematological cell counter. and second sample in

clot activator tube for serum troponin I by automated bioanalyser.

#### Procedure:

Specimen is collected into EDTA (purple) vacutainer. (5 or 7ml volume)

Then the run the sample in hematological cell counter and generate P-LCR data.

The P-LCR median was 12 fl with a reference range of 02%-20% for the 5th-95th percentiles, with a confidence interval of 95%. Normal range 02-20fL. Serological troponin I is done by minividas methods

## OBSERVATION & DISCUSSION

P-LCR	Grade	Survival outcome of patients	Serological troponin I	Sample size N=100
>12 to <14.1 fL	Mild	Good	>100 TO 1000 ng/L	59
>14.2 to <15.2fL	Moderate	Average	>1000 TO 5000 ng/L	28
>15.2 to <16 fL	Sever	Poor	>5000 TO 10000ng/L	09
>16fL	Marked	Worst	>10000 ng/L	04

#### Result:

Univariate analysis showed that there were significant associations of high PDW values with, the acute coronary artery disease, mild to marked type toxicity these various morphological changes cause the raised platelets distribution width use as a prognostic tool for survival index outcome of patients. Kruskal-Wallis tests revealed an association of raised P-LCR values with severity survival index patients:  $p < 0.0001$ , survival prognostic index of patients with higher P-LCR values had worst prognoses

#### Conclusion:

Our study is, to the best of our knowledge, the first to demonstrate an association between P-LCR and serum troponin I risk of incident MI in a general population. The association was consistent when P-LCR was modeled both as continuous and categorical variables, and the risk of recurrent MI by P-LCR correlation with troponin I pattern. Survival of patients is easily found with PLCR and troponin I correlation. There are only a few previous reports on the relation between PDW and troponin I for post MI patients from general populations. A strong association between higher P-LCR and high level of troponin I with post MI poor outcome high mortality was found in our study.<sup>13-14</sup> The risk of MI death increased by 20% for a 1-SD increment of P-LCR

<sup>14</sup>and was more than 2-3fold higher among participants in the highest quintile compared with the lowest.<sup>13</sup>, the risk of post MI mortality PLCR with normal range%.<sup>19</sup> In contrast, P-LCR is associated with Recurrent MI or myocardial mortality in this study. Greater power to detect a significant association between P-LCR and risk of recurrent MI in our study may be the main reason for the apparent discrepant relationship between P-LCR and serum troponin I for post MI. Because P-LCR is a statistical concept, it can be assumed that P-LCR is a marker of other underlying biological mechanisms.

P-LCR is suggested to be a biomarker reflecting a proinflammatory condition. Oxidative stress and inflammation increase P-LCR by impairing iron metabolism. The stronger association between P-LCR and serum troponin I for post MI in our study supports the suggestion that P-LCR reflects inflammation. Others have also speculated that the biological link between P-LCR and post MI mortality may be mediated by systemic inflammation. It has been reported that increased post MI mortality by P-LCR is confined to those with MI.

Platelet indices, like Mean Platelet Volume (MPV) and Platelet Distribution Width (PDW) are well studied markers to prognosticate patients. It was hypothesized that in acute coronary heart disease, there is increased platelet swelling and pseudopodia formation which causes an increase in the Mean Platelet Volume and Platelet Distribution Width. Among the two indices Platelet Distribution Width is found to be a more specific marker for the activation of platelets. White blood cells are a marker of inflammation and it is also well studied in patients with acute coronary syndrome which causes a rise in the inflammatory markers. White blood cell count, a marker of inflammatory response and platelet distribution width, a marker of reactivity of platelets have been studied to have unfavourable outcomes in patients with ST elevation myocardial infarction. The results of our study has shown significant association between platelet distribution width and white blood cell count with ST segment resolution in patients with STEMI thrombolysed with streptokinase. These factors can be used as simple markers for failure of thrombolysis to suggest an alternative and aggressive management protocol for

these patients who require further studies in this context.

## References

1. Kasper, Fauci, Hauser, Longo, Jameson and Loscalzo et al. Harrison's Principles Of Internal Medicine 19th edition. United States Of America. (Mc Graw Hill); volume 2; 1442.
2. Kumar et al. Robbins and Cotran Pathologic Basis Of Disease 7 th edition.( Pennsylvania. Elsevier); 571.
3. Bonow, Mann, Zipes, Libby et al. Braunwald's Heart Disease : A Text Book Of Cardiovascular Medicine 9th edition. (Philadelphia. Elsevier); 55.
4. Shuja-ur-Rehman, Sheikh S, Nazeer M. ST segment resolution post MI – a predictor of better outcomes. J Pak Med Assoc. 2008 May, 58(5) : 283-6.
5. Salim R. Hamudi Al-Obeidi, Saad H. Ahmedm, Fatma A. Obeid. Evaluation of Platelet Indices in Patients with Acute Coronary Syndrome. Mustansiriya Medical Journal, June, 12(1). 2013.
6. Lowe GD, Machado SG, Krol WF, Barton BA, Forbes CD. White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction. Thromb Haemost. 1985 Oct, 30; 54 (3) : 700-3. Brauwald E. Evolution of the management of acute myocardial infarction: a 20th century saga. Lancet 1998; 352: 1771-4.
7. Amsterdam E A et al. 2014 AHA/ACC Guidelines for the Management of Patients with Non-ST Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology. Sep 2014.
8. Y Birnbaum, B J Drew .The electrocardiogram in ST elevation acute myocardial infarction: correlation with coronary anatomy and prognosis. Postgrad Med J 2003;79:490–504.
9. Maroko P, Libby P, Ginks W, Bloor C, Shell W, Sobel B, Ross JJ. Early effects on local myocardial function and the extent of myocardial necrosis. J Clin Invest 1972; 51: 2710–6.
10. Chazov EI, Matveeva LS, Mazaev AV, Sargin KE, Sadovskaia GV, Ruda MI.

- Intracoronary administration of fibrinolytic in acute myocardial infarction. *Ter Arkh* 1976; 48: 8–19.
11. Nikhil Sikri, Amit Bardia. A History of Streptokinase use in Acute Myocardial Infarction. *Text Heart Inst J* 2007;34:318-27.
  12. Diwedi SK, Hiremath JS, Kerkar PG, Reddy KN, Manjunath CN, Ramesh SS, et al. Indigenous recombinant streptokinase vs natural streptokinase in acute myocardial infarction patients: Phase III multicentric randomized double blind trial. *Indian J Med Sci* 2005;59:200-7.
  13. Michels KB, Yusuf S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. *Circulation* 1995; 91: 476-85.
  14. Andreotti F, Pasceri V, Hackett DR, Davies GJ, Haider AW, Maseri A. Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction. *N Engl J Med* 1996; 334: 7-12.
  15. Grines CL, Topol EJ, O'Neill WW et al. Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. *Circulation* 1995; 91: 298-303.
  16. Andreotti F, Patti G. Chronobiology of the haemostatic system. In: Redfern PH, Lemmer B, eds. *Handbook of Experimental Pharmacology. Physiology and Pharmacology of Biological Rhythms.* (Springer-Verlag, Heidelberg).
  17. Andreotti F. Procoagulant and fibrinolytic factors in blood: relation to the pathogenesis and treatment of acute coronary occlusion in man. PhD thesis, 1992. ISBN 90-5412-006-1. "Relationship Of Platelet Distribution Width And White Blood Cell Count On Admission .. DOI: 10.9790/0853150802147172 www.iosrjournals.org 172 | Page
  18. Mauri F, Maggioni AP, Franzosi MG, et al. A simple electrocardiographic predictor of the outcome of patients with acute myocardial infarction treated with a thrombolytic agent. A GISSI-2 derived analysis. *J Am Coll Cardiol* 1994;24:600-7.
  19. Dissmann R, Schröder R, Busse U, et al. Early assessment of outcome by ST-segment analysis after thrombolytic therapy in acute myocardial infarction. *Am Heart J* 1994;128:851-7.
  20. Neuhaus KL, von Essen R, Vogt A, et al. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German Recombinant Plasminogen Activator Study (GRECO). *J Am Coll Cardiol* 1994;24:55-60.
  21. Shah A, Wagner GS, Granger CB et al. Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis. Reexamining the 'gold standard' for myocardial reperfusion assessment. *J Am Coll Cardiol* 2000; 35(3):666–72
  22. Ito H, Tomooka T, Sakai N et al. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. *Circulation* 1992;85(5):1699–705.
  23. van 't Hof AW, Liem A, de Boer MJ et al. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial Infarction Study Group. *Lancet* 1997;350(9078):615–9.
  24. Buckley MF, James J W, Brown D E, Whyte G S, Dean MG, Chesterman CN, et al. A novel approach to the assessment of variations in the human platelet count. *Thromb Haemost* 2000;83:480-84.
  25. Kaito K, Otsubo H, Usui N et al. *Br J haematol* 2005;128:698-702.